An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
Open Access
- 4 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-10
- https://doi.org/10.1038/s41392-020-00221-8
Abstract
No clinically available biomarkers can predict pathological complete response (pCR) for esophageal squamous cell carcinomas (ESCCs) with neoadjuvant chemoradiotherapy (nCRT). Considering that antitumor immunity status is an important determinant for nCRT, we performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of ESCCs through a multicenter analysis. During the discovery phase, 14 differentially expressed immune-related genes (DEIGs) with greater than a twofold change between pCRs and less than pCRs (SERPINE1, MMP12, PLAUR, and EPS8) was built based on the verified DEIGs from 71 cases in a Beijing training cohort, and achieved a high accuracy with an area under the receiver operating characteristic curve (AUC) of 0.970. The signature was further validated in an internal validation cohort and an integrated external cohort (Zhengzhou and Anyang cohorts) with AUCs of 0.890 and 0.859, respectively. Importantly, a multivariate analysis showed that the signature was the only independent predictor for pCR. In addition, patients with high predictive scores showed significantly longer overall and relapse-free survival across multiple centers (P < 0.05). This is the first, validated, and clinically applicable individualized immune signature of pCR and outcome prediction for ESCCs with nCRT. Further prospective validation may facilitate the combination of nCRT and immunotherapy.Keywords
This publication has 51 references indexed in Scilit:
- Guidelines for the management of oesophageal and gastric cancerGut, 2011
- EPS8 upregulates FOXM1 expression, enhancing cell growth and motilityCarcinogenesis: Integrative Cancer Research, 2010
- Microarray-Based Response Prediction in Esophageal AdenocarcinomaClinical Cancer Research, 2010
- Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal CancerAnnals of Surgery, 2009
- Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and AgeJNCI Journal of the National Cancer Institute, 2008
- Pretreatment Gene Expression Profiles Can Be Used to Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal CancerAnnals of Surgical Oncology, 2007
- Gene Expression Profiling of Localized Esophageal Carcinomas: Association With Pathologic Response to Preoperative ChemoradiationJournal of Clinical Oncology, 2006
- Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the EsophagusJournal of Clinical Oncology, 2005
- Tumor response to induction chemoradiation: influence on survival after esophagectomy☆European Journal of Cardio-Thoracic Surgery, 2003